Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CATHERINE MADELINE HREN

Allopathic & Osteopathic Physicians Dermatology

NPI
1508851478
CMS profile
295396
Location
CARY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,860.37

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,485.37 137
Education $375.00 4

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CATHERINE MADELINE HREN

NPI 1508851478 · CMS profile ID 295396

Allopathic & Osteopathic Physicians / Dermatology

CARY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508851478?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CATHERINE MADELINE HREN, NPI 1508851478, CMS profile ID 295396. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508851478?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CATHERINE MADELINE HREN, NPI 1508851478, CMS profile ID 295396. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508851478?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CATHERINE MADELINE HREN, NPI 1508851478, CMS profile ID 295396, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508851478?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $3,860.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $26.9505/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114072187 CMS
ABBVIE INC. $20.4904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103945169 CMS
PFIZER INC. $2.0904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131392659 CMS
Verrica Pharmaceuticals Inc. $23.3304/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118381984 CMS
Amgen Inc. $33.2504/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117281693 CMS
Arcutis Biotherapeutics, Inc. $21.3404/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121039194 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $33.9504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152133918 CMS
Janssen Biotech, Inc. $22.9004/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078818476 CMS
Novartis Pharmaceuticals Corporation $15.4403/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086862009 CMS
ABBVIE INC. $22.4503/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103945167 CMS
PFIZER INC. $12.3303/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131290594 CMS
E.R. Squibb & Sons, L.L.C. $15.8503/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101663101 CMS
Incyte Corporation $27.9403/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141219040 CMS
ABBVIE INC. $22.6803/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103945165 CMS
Amgen Inc. $30.8503/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117281691 CMS
UCB, Inc. $28.1603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143074988 CMS
E.R. Squibb & Sons, L.L.C. $21.6003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101663094 CMS
ABBVIE INC. $1.6303/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103945163 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $16.7703/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152133916 CMS
GENZYME CORPORATION $35.9702/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139623323 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $32.0802/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152133914 CMS
Regeneron Healthcare Solutions, Inc. $28.3402/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114072185 CMS
Arcutis Biotherapeutics, Inc. $19.5302/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121039192 CMS
PFIZER INC. $22.0002/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131141664 CMS
E.R. Squibb & Sons, L.L.C. $76.4902/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101663090 CMS
Galderma Laboratories, L.P. $14.8702/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145305143 CMS
Lilly USA, LLC $21.8002/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136095109 CMS
Janssen Biotech, Inc. $17.6902/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819299 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.1502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118038584 CMS
Dermavant Sciences, Inc. $73.3102/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127880705 CMS
Amgen Inc. $27.9102/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117281689 CMS
E.R. Squibb & Sons, L.L.C. $14.6901/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101663075 CMS
Galderma Laboratories, L.P. $14.3201/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145305141 CMS
Janssen Biotech, Inc. $15.8101/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819344 CMS
Lilly USA, LLC $13.8201/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136089222 CMS
GENZYME CORPORATION $45.2101/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139623165 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $30.1901/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152133912 CMS
ABBVIE INC. $23.2401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103945161 CMS
PFIZER INC. $20.2501/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131139652 CMS
UCB, Inc. $32.4201/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143066423 CMS
ABBVIE INC. $27.8801/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103945159 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,115.87 126
PY2020 $1,777.60 89
PY2021 $3,078.04 145
PY2022 $4,255.95 176
PY2023 $3,303.94 144
PY2024 $3,860.37 141
PY2025 $3,465.41 136

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $73,563.15 20
PY2024 Principal investigator $147,519.74 20
PY2023 Principal investigator $29,532.73 6
PY2022 Principal investigator $25,892.73 5
PY2021 Principal investigator $70,109.18 13
PY2020 Principal investigator $170,631.97 21
PY2019 Recipient $17,476.08 2
PY2019 Principal investigator $303,699.27 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,889.43 12/01/2025 Non-covered Recipient Entity
ACCELLACARE LIMITED
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223288987
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Accellacare
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235999401
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,729.38 10/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223287217
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,722.78 09/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223285281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,722.78 08/13/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284187
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,615.33 07/25/2025 Non-covered Recipient Entity
ACCELLACARE LIMITED
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283204
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,893.34 07/25/2025 Non-covered Recipient Entity
ACCELLACARE LIMITED
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,129.82 07/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223282806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,219.40 06/13/2025 Non-covered Recipient Entity
ACCELLACARE LIMITED
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281236
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,445.56 06/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281066
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,445.56 05/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279786
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,168.34 04/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277878
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,734.92 03/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276723
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 03/05/2025 Non-covered Recipient Entity
Accellacare Us Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251144
Principal investigator 1 Janssen Research & Development, LLC $2,250.00 03/05/2025 Non-covered Recipient Entity
Accellacare Us Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251765
Principal investigator 1 Janssen Research & Development, LLC $750.00 03/05/2025 Non-covered Recipient Entity
Accellacare Us Inc.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,658.20 02/25/2025 Non-covered Recipient Entity
ACCELLACARE LIMITED
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,575.38 02/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275191
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,219.40 02/05/2025 Non-covered Recipient Entity
ACCELLACARE LIMITED
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,332.24 01/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273933